We observed variable effects on viability with compounds, which were chosen based on their clinical use (i.e. doxorubicin, fludarabine) and targeting of essential cancer pathways (i.e. p53, mTOR, PI3K, AKT, BTK, BCR/ABL) (Figs 1B, S1). The gene discussed is BTK; the disease is cancer.